9 completed, 4 recruiting, 2 unknown, 1 active not recruiting. 17 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 9, Recruiting 4, Unknown 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Nausea and Vomiting: new trials by email Literature Review of Nausea and Vomiting trials Research Report on Nausea and Vomiting
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use Tradipitant, Placebo - Nausea and Vomiting, Obesity | Phase 3 | Recruiting | Vanda Pharmaceuticals | 280 | 2026-03-27 | 2026-04-20 |
| Antiemetic Fosaprepitant To Remedy Nausea and Vomiting Fosaprepitant 150 mg, Ondansetron 4 mg - Nausea and Vomiting, Nausea | Phase 2 / Phase 3 | Recruiting | Montefiore Medical Center | 200 | 2024-11-13 | 2026-05-18 |
| Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer Electroacupuncture, Antiemetic Therapy, Sham electroacupuncture - Electroacupuncture, Olanzapine-contained Four-drug Antiemetic | Phase 3 | Recruiting | Feixue Song | 370 | 2024-03-07 | 2024-03-21 |
| the Efficacy and Safety of Ondansetron Oral Soluble Pellicles Ondansetron Oral Soluble Pellicles - Nausea and Vomiting | Phase 3 | Unknown | The First Affiliated Hospital of Xinxiang Medical College | 184 | 2024-02-20 | 2024-02-28 |
| Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer Electroacupuncture, Standard antiemetic treatment, Sham electroacupuncture - Electroacupuncture, Olanzapine-contained Four-drug Antiemetic | Phase 3 | Recruiting | Jiuda Zhao | 370 | 2024-01-16 | 2025-04-02 |
| Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant) - Hematopoietic/Lymphoid Cancer, Nausea and Vomiting | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 401 | 2014-08-20 | 2025-01-28 |
| Domperidone in Treating Patients With Gastrointestinal Disorders Domperidone, Questionnaire Administration - Digestive System Disorder, Dyspepsia | Phase 3 | Active not recruiting | M.D. Anderson Cancer Center | 96 | 2012-10-23 | 2026-09-24 |
| A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy Dexamethasone, IV casopitant (placebo), IV casopitant (active) - Cancer, Chemotherapy-Induced Nausea and Vomiting | Phase 3 | Withdrawn | GlaxoSmithKline | 2009-09-01 | 2015-04-17 | |
| Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy dexamethasone, gabapentin, placebo - Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 430 | 2009-04-01 | 2016-07-06 |
| Acupressure Wristbands or Standard Care in Controlling Nausea Caused by Chemotherapy medical chart review, questionnaire administration, acupressure therapy - Anxiety Disorder, Nausea and Vomiting | Phase 3 | Completed | University of Manchester | 699 | 2008-11-01 | 2013-08-26 |
| Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer docetaxel, steroid therapy, questionnaire administration - Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer | Phase 3 | Completed | Cambridge University Hospitals NHS Foundation Trust | 320 | 2008-04-01 | 2013-08-07 |
| APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer APF530, dexamethasone, Palonosetron Hydrochloride - Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific | Phase 3 | Completed | Heron Therapeutics | 1428 | 2006-06-01 | 2026-03-02 |
| Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer dolasetron mesylate, granisetron hydrochloride, ondansetron - Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific | Phase 3 | Completed | Gary Morrow | 2001-07-01 | 2015-10-15 | |
| Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment ondansetron, placebo - Chronic Myeloproliferative Disorders, Leukemia | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 100 | 2000-10-01 | 2016-07-06 |
| Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer fatigue assessment and management, nausea and vomiting therapy, pain therapy - Fatigue, Lung Cancer | Phase 3 | Completed | NCIC Clinical Trials Group | 230 | 1997-08-01 | 2020-04-03 |
| Drugs to Reduce the Side Effects of Chemotherapy dexamethasone, granisetron hydrochloride, metoclopramide hydrochloride - Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific | Phase 3 | Completed | Swiss Cancer Institute | 267 | 1996-05-01 | 2012-07-11 |
| Lerisetron Compared With Granisetron in Preventing Nausea and Vomiting in Men Being Treated With Radiation Therapy for Stage I Seminoma granisetron hydrochloride, lerisetron, radiation therapy - Nausea and Vomiting, Testicular Germ Cell Tumor | Phase 3 | Unknown | Simbec Research | 150 | 2013-08-02 |
Nausea (17) · Vomiting (17) · Breast Neoplasms (2) · Lung Neoplasms (2) · Pain (2) · Adenocarcinoma Of Esophagus (1) · Adenocarcinoma of Lung (1) · Anxiety Disorders (1) · Blast Crisis (1) · Burkitt Lymphoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Digestive System Diseases (1) · Dyspepsia (1) · Esophageal Neoplasms (1)
Pathological Conditions, Signs and Symptoms (17) · Signs and Symptoms (17) · Signs and Symptoms, Digestive (17) · Neoplasms by Site (8) · Neoplasms (7) · Neoplasms by Histologic Type (3) · Neurologic Manifestations (3) · Breast Diseases (2) · Esophageal Diseases (2) · Gastrointestinal Diseases (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Lung Diseases (2) · Nutritional and Metabolic Diseases (2) · Respiratory Tract Diseases (2)
Granisetron (5) · Ondansetron (5) · Dexamethasone (4) · Radiotherapy (3) · Analgesia (2) · Electroacupuncture (2) · Palonosetron (2) · Acupressure (1) · Aprepitant (1) · Cisplatin (1) · Cyclophosphamide (1) · Docetaxel (1) · Domperidone (1) · Doxorubicin (1) · Drug Therapy (1)
Alliance for Clinical Trials in Oncology (3) · Cambridge University Hospitals NHS Foundation Trust (1) · Feixue Song (1) · Gary Morrow (1) · GlaxoSmithKline (1) · Heron Therapeutics (1) · Jiuda Zhao (1) · M.D. Anderson Cancer Center (1) · Montefiore Medical Center (1) · NCIC Clinical Trials Group (1) · Simbec Research (1) · Swiss Cancer Institute (1) · The First Affiliated Hospital of Xinxiang Medical College (1) · University of Manchester (1) · Vanda Pharmaceuticals (1)
United States (9) · China (3) · Canada (2) · United Kingdom (2) · Italy (1) · Switzerland (1)
Alex Molassiotis, MD (1) · Andrea Bezjak, MD, MSC, FRCPC (1) · Benjamin W Friedman, MD MS (1) · David P. Dearnaley, MD, FRCP, FRCR (1) · Debra Barton, RN, PhD, AOCN, FAAN (1) · Gary R. Morrow, PhD, MS (1) · Hugo Ford, MD (1) · John Barr, PhD (1) · Matti S. Aapro, MD (1) · Mehnaz Shafi (1) · Rudolph M. Navari, MD, PhD, FACP (1) · Steven R. Alberts, MD (1)
PMID 11773155, PMID 12377323, PMID 12562658, PMID 16198982, PMID 26289588, PMID 26921245, PMID 27410922
U10CA031946 (1)